114847-11-9

Basic information

• Product Name: 6,8,9-tris(benzyloxy)-2,4,10-trioxatricyclo[3.3.1.1~3,7~]decane
• Synonyms: 1,3,5-O-Methylidyne-2,4,6-tri-O-benzyl-myo-inositol; 114847-11-9
• CAS NO: 114847-11-9
• Molecular Formula: C₂₈H₂₈O₆
• Molecular Weight: 460.5183
• Mol File: 114847-11-9.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 573.2°C at 760 mmHg
• Flash Point: 227.2°C
• Density: 1.29g/cm³
• Vapor Pressure: 1.5E-12mmHg at 25°C
• Refractive Index: 1.628
• CAS DataBase Reference: 6,8,9-tris(benzyloxy)-2,4,10-trioxatricyclo[3.3.1.1~3,7~]decane(CAS DataBase Reference)
• NIST Chemistry Reference: 6,8,9-tris(benzyloxy)-2,4,10-trioxatricyclo[3.3.1.1~3,7~]decane(114847-11-9)
• EPA Substance Registry System: 6,8,9-tris(benzyloxy)-2,4,10-trioxatricyclo[3.3.1.1~3,7~]decane(114847-11-9)

Safety Data

• Hazardous Substances Data: 114847-11-9(Hazardous Substances Data)

Upstream product

• 100-39-0 benzyl bromide 
• 120268-33-9 4/6-O-benzyl-myo-inositol 1,3,5-monoorthoformate 
• 98510-20-4 myo-Inositol orthoformate 
• 100-44-7 benzyl chloride 

Downstream Products

• 129952-32-5 (1R,5S,6R,7R,8R,9R)-6,8,9-Tris-benzyloxy-3-methyl-2,4-dioxa-bicyclo[3.3.1]nonan-7-ol 
• 227177-05-1 2,4,6-tri-O-benzyl-1,5-O-ethylidene-DL-myo-inositol 
• 129952-31-4 (+/-)-2,4,6-tri-O-benzyl-1,3-O-methylidene-D-myo-inositol 
• 129952-31-4 (1R,5S,6R,7R,8R,9R)-6,8,9-Tris-benzyloxy-2,4-dioxa-bicyclo[3.3.1]nonan-7-ol 
• 227177-05-1 (1R,5S,6S,7R,8S,9R)-6,8,9-Tris-benzyloxy-3-methyl-2,4-dioxa-bicyclo[3.3.1]nonan-7-ol 
• 114828-09-0 2,4,6-tri-O-benzyl-myo-inositol 1,3-bis(diphenylphosphate) 
• 1374660-06-6 meso-2,4,6-tri-O-benzyl-1,3-O-methylidene-D-myo-inositol-5-(didecyl phosphate) 
• 1374792-73-0 meso-2,4,6-tri-O-benzyl-D-myo-inositol-5-(didecyl phosphate) 
• 1374792-74-1 meso-D-myo-inositol-5-(didecyl phosphate) 

Relevant articles and documents

Synthesis and screening of novel inositol phosphonate derivatives for anticancer functions in vitro

Phosphonates have been frequently used as suitable isosteric and isoelectronic replacements for biologically important phosphates in the development of drugs or drug candidates because of their stability toward the action of phosphatases and other enzymes. In this paper, 12 mono-phosphonate inositol compounds were prepared with phosphonate instead of phosphate by two kinds of strategies, nucleophilic substitution and Arbuzov rearrangement, respectively. All compounds were evaluated in vitro for their activity against non-small cell lung cancer (NSCLC) cell line A549. Two compounds (3ac and 3bb) exhibited good antitumor activity at 10 μg/mL.

A short and efficient route from myo - To neo -inositol

An efficient route from myo- to neo-inositol is described. The key steps of the sequence are oxidation of the hydroxy group at C-5 to the corresponding ketone, followed by a highly (dr = 7.8:1) stereoselective reduction. The route includes nine steps with an overall yield of 51% and is therefore superior to all hitherto reported methods for the preparation of neo-inositol. Georg Thieme Verlag Stuttgart New York.

Synthesis of 1-O-(2-oxo-benzo-1,3,2-dioxaphosphaocan-2-yl)-myo-inositol and 3,5-dideoxy-1-O-(2-oxo-benzo-1,3,2-dioxaphosphaocan-2-yl)-myo-inositol as prodrugs of inositolmonophosphatase ligands

1-O-(2-oxo-benzo-1,3,2-dioxaphosphaocan-2-yl)-myo-inositol and 3,5- dideoxy-1-O-(2-oxo-benzo-1,3,2-dioxaphosphaocan-2-yl)-myo-inositol were prepared by selective modifications of myo-inositol. Phosphorylation used the phosphite method by means of the 2(N,N-di-isopropylamino)-benzo-1,3,2- dioxaphosphaocane.